Advertisement

Unscheduled vaginal bleeding with progestin-only contraceptive use

Published:December 14, 2016DOI:https://doi.org/10.1016/j.ajog.2016.12.008
      Nearly 20% of women using contraception are using progestin-only contraception, including progestin-only pills, depot-medroxyprogesterone acetate, subdermal etonogestrel implants, and levonorgestrel intrauterine devices. This number will continue to grow with the increased provision of long-acting reversible contraception. Although overall satisfaction among women using progestin-only contraception is high, dissatisfaction and discontinuation may be associated with unscheduled bleeding and spotting. The exact etiology of irregular bleeding associated with progestin-containing contraceptives is not completely understood, yet several mechanisms have been suggested. Several therapies targeting these mechanisms have been evaluated with mixed results. This paper will review the physiology and management of unscheduled bleeding with progestin-containing contraceptives.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Moreau C.
        • Cleland K.
        • Trussel J.
        Contraceptive discontinuation attributed to method dissatisfaction in the United States.
        Contraception. 2007; 76: 267-272
        • Grunloh D.S.
        • Casner T.
        • Secura G.M.
        • Peipert J.F.
        • Madden T.
        Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use.
        Obstet Gynecol. 2013; 122: 1214-1221
        • Diedrich J.T.
        • Zhao Q.
        • Madden T.
        • Secura G.
        • Peipert J.F.
        Three-year continuation of reversible contraception.
        Am J Obstet Gynecol. 2015; 213: 662.e1-662.e8
        • Speroff L.
        • Darney P.D.
        Oral contraception.
        in: A clinical guide for contraception. Lippincott Williams & Wilkins, Philadelphia PA2011: 109
        • ESHRE Capri Workshop Group
        Ovarian and endometrial function during hormonal contraception.
        Hum Reprod. 2011; 16: 1527
        • Stanczyk F.Z.
        Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.
        Rev Endocr Metab Disord. 2002; 3: 211-224
        • McCann M.F.
        • Potter L.S.
        Progestin-only oral contraception: a comprehensive review.
        Contraception. 1994; 50: S1
      1. Faculty of Sexual and Reproductive Healthcare Clinical Guidance. Progestogen-only pills. 2008. Available at: http://www.fsrh.org/documents/progestogen-only-pills-jun-2009. Accessed November 10, 2016.

        • Belsey E.M.
        Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.
        Contraception. 1988; 38: 181
        • Broome M.
        • Fotherby K.
        Clinical experience with the progestogen-only pill.
        Contraception. 1990; 42: 489-495
        • Kovacs G.
        Progestogen-only pills and bleeding disturbances.
        Hum Reprod. 1996; 11: 20-23
        • Kaunitz A.M.
        Long-acting injectable contraception with depot medroxyprogesterone acetate.
        Am J Obstet Gynecol. 1994; 170: 1543
        • Jain J.
        • Dutton C.
        • Nicosia A.
        • Wajszczuk C.
        • Bode F.R.
        • Mishell Jr., D.R.
        Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.
        Contraception. 2004; 70: 11-18
        • Jeppsson S.
        • Gershagen S.
        • Johansson E.D.
        • Rannevik G.
        Plasma levels of medroxyprogesterone-acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotropin and prolactin in women during long term use of depo-MPA (Depo-Provera) as a contraceptive agent.
        Acta Endocrinol. 1982; 99: 339-343
        • Hubacher D.
        • Lopez L.
        • Steiner M.J.
        • Dorflinger L.
        Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons.
        Contraception. 2009; 80: 113
        • Arias R.D.
        • Jain J.K.
        • Brucker C.
        • Ross D.
        • Ray A.
        Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous 104 mg.
        Contraception. 2006; 74: 234-238
        • Fraser I.S.
        A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives.
        Contraception. 1983; 28: 385-397
        • McNicholas C.
        • Maddipati R.
        • Zhao Q.
        • Swor E.
        • Peipert J.F.
        Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the US Food and Drug Administration–approved duration.
        Obstet Gynecol. 2015; 125: 599-604
        • Ali M.
        • Akin A.
        • Bahamondes L.
        • et al.
        Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to the levonorgestrel-releasing subdermal implant.
        Hum Reprod. 2016; 31: 2491-2498
        • Raymond E.G.
        Contraceptive implants.
        in: Hatcher R.A. Trussell J. Nelson A. Cates W. Stewart F. Kowal D. Contraceptive technology. Ardent Media, New York (NY)2007: 147-148
        • Wenzl R.
        • van Beek A.
        • Schnabel P.
        • Huber J.
        Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
        Contraception. 1998; 58: 283-288
        • Abdel-Aleem H.
        • d’Arcangues C.
        • Vogelsong K.M.
        • Gaffield M.L.
        • Gulmezoglu A.M.
        Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
        Cochrane Database Syst Rev. 2013; : CD003449
        • Mansour D.
        • Korver T.
        • Marintcheva-Petrova M.
        • Fraser I.S.
        The effects of Implanon on menstrual bleeding patterns.
        Eur J Contracept Reprod Healthcare. 2008; 13: 13-28
        • Mansour D.
        • Bahamondes L.
        • Critchley H.
        • Darney P.
        • Fraser I.S.
        The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users.
        Contraception. 2011; 83: 202-210
        • Hohmann H.
        • Creinin M.D.
        The contraceptive implant.
        Clin Obstet Gynecol. 2007; 50: 907-917
        • Guiahi M.
        • McBride M.
        • Sheeder J.
        • Teal S.
        Short-term treatment of bothersome bleeding for ENG implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial.
        Obstet Gynecol. 2015; 126: 508-513
        • Lewis R.A.
        • Taylor D.
        • Natavio M.F.
        • Melamed A.
        • Felix J.
        • Mishell D.
        Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability.
        Contraception. 2010; 82: 491-496
        • ESHRE Capri Workshop Group
        Intrauterine devices and intrauterine systems.
        Hum Reprod Update. 2008; 14: 197-208
        • Rowe P.
        • Farley T.
        • Peregoudov A.
        • et al.
        Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A.
        Contraception. 2016; 93: 498-506
        • Eisenberg D.L.
        • Schreiber C.A.
        • Turok D.K.
        • Teal S.B.
        • Westhoff C.L.
        • Creinin M.D.
        Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
        Contraception. 2015; 92: 10-16
      2. Kyleena. Manufacturer package insert. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Kyleena_PI.pdf. Accessed November 12, 2016.

      3. Skyla. Manufacturer package insert. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf. Accessed August 1, 2016.

      4. Mirena. Manufacturer package insert. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed August 1, 2016.

      5. Liletta. Manufacturer package insert. Available at: http://pi.actavis.com/data_stream.asp?product_group=1960&p=pi&language=E. Accessed August 1, 2016.

        • Pakarinen P.I.
        • Luukkainen T.
        • Laine H.
        The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation.
        Hum Reprod. 1995; 10: 2390-2394
        • Guttinger A.
        • Critchley H.O.
        Endometrial effects of intrauterine levonorgestrel.
        Contraception. 2007; 75: 593-598
        • Lethaby A.
        • Duckitt K.
        • Farquhar C.
        Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding (Review).
        Cochrane Database Syst Rev. 2013; : CD000400
        • Tantiwattanakul P.
        • Taneepanichskul S.
        Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users.
        Contraception. 2004; 70: 277-279
        • Nathirojanakun P.
        • Taneepanichskul S.
        • Sappakitkumjorn N.
        Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users.
        Contraception. 2006; 73: 584-587
        • Phaliwong P.
        • Taneepanichskul S.
        The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use.
        J Med Assoc Thai. 2004; 87: S64-S68
        • Diaz S.
        • Croxatto H.B.
        • Pavez M.
        • Belhadj H.
        • Stern J.
        • Sivin I.
        Clinical assessment of treatments for prolonged bleeding in users of Norplant implants.
        Contraception. 1990; 42: 97-109
        • Archer D.F.
        • Philput C.B.
        • Levine A.S.
        • et al.
        Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in LNG subcutaneous implant users.
        Contraception. 2008; 78: 106-112
        • Kaewrudee S.
        • Taneepanichskul S.
        • Jaisamraun U.
        • Reinprayoon D.
        The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
        Contraception. 1999; 60: 25-30
        • d’Arcangues C.
        • Piaggio G.
        • Brache V.
        • et al.
        Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding.
        Contraception. 2004; 70: 451-462
        • Buasang K.
        • Taneepanichskul S.
        Efficacy of celecoxib on controlling irregular uterine bleeding secondary to Jadelle use.
        J Med Assoc Thai. 2009; 92: 301-307
        • Madden T.
        • Proehl S.
        • Allsworth J.E.
        • Secura G.M.
        • Peipert J.F.
        Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial.
        Am J Obstet Gynecol. 2012; 206: 129.e1-129.e8
        • Said S.
        • Sadek W.
        • Rocca M.
        • et al.
        Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation.
        Hum Reprod. 1996; 11: 1-13
        • Hou M.Y.
        • McNicholas C.
        • Creinin M.D.
        Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial.
        Eur J Contracept Reprod Health Care. 2016; 15: 1-6
        • Alvarez-Sanchez F.
        • Brache V.
        • Thevenin F.
        • Cochon L.
        • Faundes A.
        Hormonal treatment for bleeding irregularities in Norplant implant users.
        Am J Obstet Gynecol. 1996; 174: 919-922
        • Boonkasemsanti W.
        • Reinprayoon D.
        • Pruksananonda K.
        • et al.
        The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
        Hum Reprod. 1996; 11: 115-123
        • Abdel-Aleem H.
        • Shaaban O.M.
        • Abdel-Aleem M.A.
        • Fetih G.N.
        Doxycycline in the treatment of bleeding with DMPA: a double-blinded RCT.
        Contraception. 2012; 86: 224-230
        • Weisberg E.
        • Hickey M.
        • Palmer D.
        • et al.
        A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.
        Hum Reprod. 2006; 21: 295-302
        • Weisberg E.
        • Hickey M.
        • Palmer D.
        • et al.
        A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users.
        Hum Reprod. 2009; 24: 1582-1861
        • Senthong A.J.
        • Taneepanichskul S.
        The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use.
        J Med Assoc Thai. 2009; 92: 461-465
        • Phupong V.
        • Sophnsritsuk A.
        • Taneepanichskul S.
        The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use.
        Contraception. 2006; 73: 253-256
        • Sordal T.
        • Inki P.
        • Draeby J.
        • et al.
        Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial.
        Obstet Gynecol. 2013; 121: 934-941
        • Jain J.K.
        • Nicosia A.F.
        • Nucatola D.L.
        • Lu J.J.
        • Kuo J.
        • Felix J.C.
        Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate.
        Steroids. 2003; 68: 1115-1119
        • Massai M.R.
        • Pavez M.R.
        • Fuentealba B.
        • Croxatto H.
        • d’Arcangues C.
        Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users.
        Contraception. 2004; 70: 442-450
        • Simmons K.
        • Edelman A.
        • Fu R.
        • Jensen J.
        Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial.
        Contraception. 2017; 95: 198-204
        • Abdel-Aleem H.
        • Shaaban O.M.
        • Amin A.F.
        • Abdel-Aleem A.M.
        Tamoxifen treatment of bleeding irregularities associated with Norplant use.
        Contraception. 2005; 72: 432-437